That $335M JV Bay­er set up on CRISPR/Cas9? They’re let­ting the biotech part­ner car­ry on

Bay­er com­mit­ted $300 mil­lion to set up a joint ven­ture on CRISPR/Cas9 tech with CRISPR Ther­a­peu­tics $CR­SP. But they’re hand­ing off con­trol now to the small­er biotech while re­tain­ing a cou­ple of opt-ins for pro­grams near­ing an IND.

Bay­er $BAY made much of the fact that they were go­ing all-in on gene edit­ing when they did their deal 3 years ago with CRISPR Ther­a­peu­tics, which pitched $35 mil­lion in on their end. This was the cor­ner­stone of their plan to set up new JVs that could make some se­ri­ous leap for­wards in hot new R&D spaces. Now CRISPR will have full man­age­ment con­trol of Case­bia as they pur­sue pro­grams in he­mo­phil­ia, oph­thal­mol­o­gy and au­toim­mune dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.